Jun. 19 at 2:15 PM
eXoZymes says its platform can also produce cannabinoids, terpenes, and flavonoids.
A May 2026 investor presentation from eXoZymes (Nasdaq:
$EXOZ ) put the spotlight on the wider range of compounds its platform can make. Chairman Chris Marlett said cannabinoids are next in line, with terpenes and flavonoids behind them, and that the company is building its patents around the methods used to make these compounds.
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1
Marlett traced the cannabinoid work back to the company’s earliest days: “So cannabinoids are next. Actually, ironically, it was the first thing we started to make. We started to make cannabinoids. We got grants to make it and we demonstrated that we could get yields.”
The presentation also covered:
• A platform the company says also extends to terpenes and flavonoids
• A strategy to patent the methods used to make natural compounds, plus composition patents on engineered analogs and enzymes
• A partnership model spanning contract manufacturers, supplement makers, and pharmaceutical companies
• Recognition in scientific and news publications and grant funding the company cites as validation
Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris
eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology. The company is building a pipeline of natural compounds and engineered analogs across nutraceutical and pharmaceutical applications. Learn more at https://exozymes.com.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
$DNLI,
$TWST,
$DNA,
$ARKG